Double dose of antiviral drug offers no added benefit in severe influenza

(Wellcome Trust) Giving double doses of the antiviral drug oseltamivir, or Tamiflu, offers no clinical or virological advantages over a standard dose for patients admitted to hospital with severe influenza infection, according to a randomized trial published today and funded by the Wellcome Trust, US National Institute of Allergy and Infectious Diseases and the Singapore National Medical Research Council.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news